SNTI — Senti Biosciences Balance Sheet
0.000.00%
- $56.24m
- $34.67m
- 23
- 18
- 43
- 16
Annual balance sheet for Senti Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 30.5 | 56 | 98.6 | 35.9 | 48.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.317 | 0.483 | 0.626 | 17.7 | 1.8 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 31.7 | 60.2 | 103 | 71.2 | 59 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 16.1 | 33.1 | 74.6 | 41.6 | 35.2 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 48.3 | 96.7 | 181 | 119 | 97.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.87 | 14.5 | 18.1 | 12.7 | 13.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 17.4 | 36.3 | 53.5 | 52.6 | 47.1 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 30.9 | 60.4 | 127 | 66.9 | 50.8 |
| Total Liabilities & Shareholders' Equity | 48.3 | 96.7 | 181 | 119 | 97.8 |
| Total Common Shares Outstanding |